Abstract
AbstractCOP‐1, a synthetic basic random amino acid copolymer, is effective in suppression of experimental allergic encephalomyelitis in guinea pigs, rabbits, mice, rhesus monkeys and baboons, and of the exacerbating‐remitting type of multiple sclerosis in humans. COP‐1 is cross‐reactive at the monoclonal antibody level with the basic protein of the myelin sheath of the brain (BP), and the suppressive effect may be related to this immunological cross‐reaction. Indeed, competition for the major histocompatibility complex (MHC) class II antigen, between BP and COP‐1, may be one explanation for its beneficial effect in the disease. This polymeric drug, COP‐1, may, therefore, be considered also an immunomodulatory vaccine, and may serve as a prototype to vaccines against autoimmune diseases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
